Evidence map›Paper›PMID 38792196›Full record

ArticleMolecules (Basel, Switzerland)2024

The Cholinergic Selectivity of FDA-Approved and Metabolite Compounds Examined with Molecular-Docking-Based Virtual Screening.

Michael D Gambardella, Yigui Wang, Jiongdong Pang

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael D GambardellaDepartment of Chemistry and Biochemistry, Southern Connecticut State University, New Haven, CT 06515, USA.
Yigui WangDepartment of Chemistry and Biochemistry, Southern Connecticut State University, New Haven, CT 06515, USA.
Jiongdong PangDepartment of Chemistry and Biochemistry, Southern Connecticut State University, New Haven, CT 06515, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The search for selective anticholinergic agents stems from varying cholinesterase levels as Alzheimer's Disease progresses from the mid to late stage. In this computational study, we probed the selectivity of FDA-approved and metabolite compounds against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with molecular-docking-based virtual screening. The results were evaluated using locally developed codes for the statistical methods. The docking-predicted selectivity for AChE and BChE was predominantly the consequence of differences in the volume of the active site and the narrower entrance to the bottom of the active site gorge of AChE.

Indexed as

AcetylcholinesteraseButyrylcholinesteraseCatalytic DomainCholinesterase InhibitorsMolecular Docking SimulationAlzheimer DiseaseHumansUnited StatesUnited States Food and Drug AdministrationAcetylcholinesteraseButyrylcholinesteraseCholinesterase InhibitorsacetylcholinesterasebutyrylcholinesterasecholinesteraseFDAmetabolitesmolecular dockingmolecular dynamicsstatistical analysesvirtual screeningvisualization

Identifiers

PMID38792196
PMCPMC11124253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.